Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivantinib + Cetuximab vs Cetuximab in Recurrent/Metastatic Head and Neck Cancer
NCT01696955Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2012
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tivantinib in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 1 year. Started Aug 2012; status: completed.
02
Drugs
tivantinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01696955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01696955.